Skip to content

Depression research published in 2023

Page 7 of 24: studies 121 to 140 of 466, newest first. Back to the depression overview

Studies

Natural psychedelics in the treatment of depression; a review focusing on neurotransmitters.

Fitoterapia September 1, 2023 Samane Jahanabadi, Shayan Amiri, Mehdi Karkeh-Abadi et al. 14 citations

Natural psychedelic compounds are emerging as potential novel therapeutics in psychiatry. This review will discuss how natural psychedelics exert their neurobiological therapeutic effects, and how different neurotransmission systems mediate the effects of these compounds. Further, current therapeutic strategies for depression, and novel mechanism of action of natural psychedelics in the...

Psychedelic Use Among Psychiatric Medication Prescribers: Effects on Well-Being, Depression, Anxiety, and Associations with Patterns of Use, Reported Harms, and Transformative Mental States.

Psychedelic Medicine September 1, 2023 Zachary Herrmann, Adam W. Levin, Steven P Cole et al. 9 citations

Mental health problems including depression, anxiety, suicide, and burnout are common among health care providers. Resilience and well-being are factors thought to protect against these incidents. Clinical trials and naturalistic studies of psychedelic compounds have shown decreases in depression, anxiety, and suicidality while suggesting improvements in well-being. This secondary analysis of a...

Predictors of Pharmacy Students' Attitudes About the Therapeutic Use of Psilocybin.

Cureus September 1, 2023 Nm Mahmudul Alam Bhuiya, Robin J Jacobs, Karina Wang et al. 3 citations

Background Psilocybin has been studied for its potential therapeutic benefits, particularly for the treatment of psychiatric disorders such as anxiety, depression, and obsessive-compulsive disorder. While more research is needed as psilocybin-assisted therapy becomes more prevalent, future pharmacists will probably be involved at some level. At present, pharmacists receive minimal training on...

Single-Dose Psilocybin Treatment for Major Depressive Disorder

JAMA August 31, 2023 Charles L. Raison, Gerard Sanacora, Joshua Woolley et al. 493 citations

Importance Psilocybin shows promise as a treatment for major depressive disorder (MDD). Objective To evaluate the magnitude, timing, and durability of antidepressant effects and safety of a single dose of psilocybin in patients with MDD. Design, Setting, and Participants In this phase 2 trial conducted between December 2019 and June 2022 at 11 research sites in the US, participants were...

DOI: 10.1001/jama.2023.14530 (opens in new tab) Full text (opens in new tab) Psilocybin therapy Clinical depression treatment Psychedelic medicine Mental health research +1

Mental Gravity: Depression as Spacetime Curvature of the Self, Mind, and Brain

Entropy August 30, 2023 Lachlan Kent 4 citations

The principle of mental gravity contends that the mind uses physical gravity as a mental model or simulacrum to express the relation between the inner self and the outer world in terms of "UP"-ness and "DOWN"-ness. The simulation of increased gravity characterises a continuum of mental gravity which states includes depression as the paradigmatic example of being down, low, heavy, and slow. The...

Effects of Web-Based Mindfulness-Based Interventions on Anxiety, Depression, and Stress Among Frontline Health Care Workers During the COVID-19 Pandemic: Systematic Review and Meta-Analysis.

Journal of Medical Internet Research August 29, 2023 Jia-Ming Yang, Hua Ye, Yi Long et al.

Background: Since 2019, the COVID-19 outbreak has spread around the world, and health care workers, as frontline workers, have faced tremendous psychological stress. Objective: The purpose of this study is to explore whether web-based mindfulness-based interventions continue to have a positive impact on anxiety, depression, and stress among health care workers during the COVID-19 pandemic....

Mindfulness-Based Interventions During Pregnancy and Long-Term Effects on Postpartum Depression and Maternal Mental Health: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Journal of Integrative and Complementary Medicine August 28, 2023 Sara Trapani, Martina Caglioni, Giulia Villa et al.

Objectives: Preventing postpartum depression (PPD) is a public health goal. The scientific literature has demonstrated the short-term efficacy of Mindfulness-Based Interventions (MBIs) delivered during pregnancy on PPD. Nevertheless, the long-term outcomes of MBIs are still unclear. Design: Systematic review and meta-analysis of randomized controlled trials (RCTs). Four databases were searched...

Utilization of Ketamine for Major Depression

Journal of Exploratory Research in Pharmacology August 28, 2023 Ryan Dao, Amit Aggarwal 2 citations

Major depressive disorder (MDD) continues to be a prevalent disease worldwide. While selective serotonin reuptake inhibitors and other medications continue to be prescribed, further research has been conducted toward other treatment modalities. Within the past decade, ketamine, an N-methyl-d-aspartate receptor antagonist, has been extensively studied as a new treatment for MDD. Recent studies...

Mindfulness-enhanced internet-based cognitive behavioural therapy for anxiety and depression: Outcomes in routine care.

Journal of Affective Disorders August 23, 2023 Claudia Hurwitz, Christine T Shiner, Maria J Sharrock et al.

Background: Clinical trials support the efficacy of mindfulness-enhanced, internet-based cognitive behavioural therapies (CBT) in reducing anxiety and depression symptom severity. However, it is unclear how effective these interventions are when delivered in routine clinical care settings. This study investigated the utilisation and treatment outcomes of an online mindfulness-enhanced CBT...

A quantitative textual analysis of the subjective effects of ayahuasca in naive users with and without depression

Research Square August 23, 2023 Lucas Villar Magalhães da Cruz, Bheatrix Bienemann Favero, Fernanda Palhano-Fontes et al. preprint

Abstract Ayahuasca is a brew with psychoactive properties that has been used as an entheogen for centuries, with more recent studies suggesting it is a promising treatment for some clinical disorders. Although there is an emerging scientific literature on its effects, to the best of our knowledge no study has explored the self-reported experiences of first-time ayahuasca users with quantitative...

DOI: 10.21203/rs.3.rs-3170538/v1 (opens in new tab) Full text (opens in new tab) Ayahuasca Depression economics Traditional medicine Anthropology

Psilocybin therapy for treatment resistant depression: prediction of clinical outcome by natural language processing

Psychopharmacology August 22, 2023 Robert F. Dougherty, Patrick Clarke, Merve Atli et al. 21 citations

Abstract Rationale Therapeutic administration of psychedelics has shown significant potential in historical accounts and recent clinical trials in the treatment of depression and other mood disorders. A recent randomized double-blind phase-IIb study demonstrated the safety and efficacy of COMP360, COMPASS Pathways’ proprietary synthetic formulation of psilocybin, in participants with...

Attenuation of severe ketamine-induced neuropsychiatric side effects by lamotrigine in a patient with treatment resistant bipolar depression: A case report

Psychiatry Research Case Reports August 20, 2023 Brian S. Barnett, Amit Anand

Though usually mild, neuropsychiatric side effects of intravenous ketamine for depression occasionally result in treatment discontinuation. Two small clinical trials of healthy subjects have indicated that lamotrigine pre-treatment may attenuate these side effects, though two other trials, one in patients with unipolar depression and one in healthy male volunteers, did not support these...

DOI: 10.1016/j.psycr.2023.100167 (opens in new tab) Ketamine Lamotrigine Discontinuation Depression economics +6

Effect of postoperative application of esketamine on postoperative depression and postoperative analgesia in patients undergoing pancreatoduodenectomy: a randomized controlled trial protocol.

Trials August 19, 2023 Kaili Yu, Zhenguo Song, Bowen Zhang et al.

Pancreatoduodenectomy (PD) is traumatic, difficult to perform, and has a high incidence of postoperative complications and perioperative mortality. Postoperative complications and pain occur frequently and seriously affect the psychological status of patients. Esketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has analgesic and antidepressant effects. In this study, we aim to...

DOI: 10.1186/s13063-023-07575-8 (opens in new tab) Full text (opens in new tab) Esketamine Pancreatoduodenectomy Postoperative analgesia Postoperative depression

Change in Negative Affective Bias following a Single Ketamine Treatment for Treatment-Resistant Depression

Depression and Anxiety August 19, 2023 Anna J. Harvey, Stevan Nikolin, Nicholas Chand et al. 4 citations

Ketamine has recently emerged as a highly effective new treatment for people with treatment-resistant depression with rapid antidepressant effects. However, these effects are often short lasting, and the potential cognitive mechanisms underlying the therapeutic effects, such as effects on emotional processing bias, remain poorly understood. In the present study, we explored potential changes in...

Effects of Mindfulness-Based Elder Care (MBEC) on symptoms of depression and anxiety and spiritual well-being of institutionalized seniors with disabilities: a randomized controlled trial

BMC Geriatrics August 18, 2023 Yvonne Hsiung, Yi‐Heng Chen, Li-Chan Lin et al. 15 citations

Abstract Background Despite the need to incorporate seniors from various settings into mindfulness-based empirical research, issues of geriatric frailties and non-compliance remain. This study aimed to evaluate the effects of a mindfulness-based elder care (MBEC) program on mental health and spiritual well-being among seniors with disabilities in long-term care residential settings. Methods...

Psychedelic Drugs used in the Treatment of Depression: A Literature Review

Global Journal of Medical Research August 18, 2023 Matheus Amorim Grigorio, E. S. B. E. Silva, Vitória Patrícia Rodrigues Cunha et al.

Introduction: When analyzing the main depressive conditions and their treatments, we understand that it is not so simple to take care of psychosomatic conditions, because it is a pathology that has a significant epidemiological aspect and needs a good approach, therefore, psychedelic drugs come in as a an important alternative as a treatment. Methodology: This is a literature review with...

A Proposal to Study the Safety and Efficacy of Psilocybe cubensis in Preclinical and Clinical Studies as a Therapeutic Alternative for Major Depressive Disorder

Journal of Psychoactive Drugs August 18, 2023 Raul Escamilla, María Eva González-Trujano, Jesús M. González Mariscal et al. 7 citations

The pharmacological treatment of depression consists of taking antidepressant drugs for prolonged periods; its modest therapeutic effect can often be associated with significant adverse effects, while its discontinuation can lead to relapses. Psilocybin is today a novel and breakthrough therapy for major depression. It is a natural alkaloid in Psilocybe mushrooms, which are endemic to Mexico....

DOI: 10.1080/02791072.2023.2246459 (opens in new tab) Psychedelic therapy Major depression Psilocybe mushrooms Psychedelic medicine +3

Psilocybin‐assisted psychotherapy for treatment‐resistant depression: Which psychotherapy?

International Journal of Mental Health Nursing August 17, 2023 Marie Crowe, Jenni Manuel, Dave Carlyle et al. 6 citations

Abstract This perspective paper explores the choice of psychotherapy for psilocybin‐assisted psychotherapy for treatment‐resistant depression. There is evidence to support the use of some psychotherapies in treating ‘treatment‐resistant’ depression, and emerging evidence for the efficacy of psilocybin. The next step which is the focus of this paper is to identify psychotherapies that are both...

Stress appraisal and emotion regulation mediate the association between mindfulness and affect in cancer patients: Differential mechanisms for positive and negative affect.

Psycho-Oncology August 16, 2023 Puttichai Tungtong, Adelita V Ranchor, Maya J. Schroevers

Objective: Cancer patients are at an increased risk for affective problems, including feelings of anxiety and depression. Mindfulness has been linked to an array of benefits for affective functioning in various populations including cancer patients, but the mechanisms underlying this relationship are still poorly understood. Based on emotion-regulation and stress-coping models, this study...

Evaluation of major depressive disorder using 7 Tesla phase sensitive neuroimaging before and after mindfulness-based cognitive therapy.

Journal of Affective Disorders August 15, 2023 Angela Jakary, Janine M Lupo, Scott Mackin et al.

We applied 7 Tesla phase sensitive imaging to evaluate the impact of brain iron levels on depression severity and cognitive function in individuals with major depressive disorder (MDD) treated with mindfulness-based cognitive therapy (MBCT). Seventeen unmedicated MDD participants underwent MRI, evaluation of depression severity, and cognitive testing before and after receiving MBCT, compared to...